[Source: GenomeWeb News] – Intrinsic Bioprobes, a private clinical diagnostics developer, said today that it has licensed two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, a Johnson & Johnson company.
The blood-circulating proteins covered under the license, which were discovered using Intrinsic’s mass spectrometry-based technology, have been linked with the presence of pre-diabetes and type 2 diabetes, the Tempe, Ariz.-based company said.
For more information: Ortho-Clinical Diagnostics Licenses Intrinsic Bioprobes’ Markers